Litcius/Paper detail

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

Maximilian J. Hochmair, Karim Vermaelen, Giannis Mountzios, Enric Carcereny, Christophe Dooms, Se‐Hoon Lee, Éva Mórocz, Terufumi Kato, Tudor–Eliade Ciuleanu, Grace K. Dy, Bárbara Parente, Kenneth J. O’Byrne, Quincy S. Chu, Gilberto de Castro, Nicolas Girard, Wendy Snyder, Qui Tran, William Kormany, Brett E. Houk, Bhakti Mehta, Alessandra Curioni‐Fontecedro

2024European Journal of Cancer16 citationsDOI

Topics & Concepts

KRASMedicinePharmacokineticsLung cancerOncologyInternal medicinePharmacologyCancerColorectal cancerLung Cancer Treatments and MutationsLung Cancer Research StudiesPI3K/AKT/mTOR signaling in cancer
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC | Litcius